Literature DB >> 8845316

Non-surgical management of early breast cancer in the United Kingdom: radiotherapy fractionation practices. Clinical Audit Sub-committee of the Faculty of Clinical Oncology, Royal College of Radiologists, and the Joint Council for Clinical Oncology.

J R Yarnold1, P Price, G G Steel.   

Abstract

A national survey of British radiotherapy schedules used in women with early breast cancer was undertaken to document variation in treatment practices and to consider its clinical significance. Although the variation is considerable, the analysis suggests that the majority of schedules in use are very similar in terms of treatment intensity when allowance is made for fraction size and overall time. Half the respondents used one of three dosage schedules, which probably differ very little in terms of late normal-tissue effects and tumour control from a conventional schedule giving 50 Gy in daily 2 Gy fractions. Eighty-two percent of respondents were using schedules that are equivalent to a dose of between 45 Gy and 50 Gy in 2 Gy fractions. The study suggests that the protocols in use by a minority of respondents may be unduly conservative or aggressive, and it leads to the proposal that oncologists should set up trials comparing commonly used schedules as a matter of urgency.

Entities:  

Mesh:

Year:  1995        PMID: 8845316     DOI: 10.1016/s0936-6555(05)80604-1

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

1.  Fears over radiotherapy fractionation regimens in breast cancer. Proposed Uk trial needs to define techniques as well as numbers of treatments.

Authors:  A Rodger
Journal:  BMJ       Date:  1998-07-18

2.  Brachial plexus neuropathy after radiotherapy for breast cancer.

Authors:  M F Spittle
Journal:  BMJ       Date:  1995-12-09

3.  Hypofractionation in post-mastectomy breast cancer patients: seven-year follow-up.

Authors:  Hany Eldeeb; Iman Awad; Osman Elhanafy
Journal:  Med Oncol       Date:  2012-02-22       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.